Review Article

Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy

Table 2

FOLFIRINOX regimen in patients with borderline resectable or locally advanced unresectable pancreatic cancer.

AuthorStudy design ptsORRResection rateR0 resections1-year PFS

Hosein et al. [16]Retrospective1839%28%83%
Gunturu et al. [17]Retrospective1650%
Peddi et al. [18]Registry study2334%75%
Blazer et al. [19]Retrospective4354%42%
Vasile et al. [20]Phase II3237%41%
Kunzmann et al. [21]Phase II*863%37%

Sequential regimen including FOLFIRINOX and nab-paclitaxel plus gemcitabine.